Corcept Therapeutics | CORT - Equity Capital And Reserves


Corcept Therapeutics reported $631.9M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Alaunos Therapeutics USD 2.8M 858K Sep/2025
ANI Pharmaceuticals USD 505.82M 69.06M Sep/2025
Ardelyx USD 154.28M 14.75M Sep/2025
Aurora Cannabis CAD 567.1M 21.58M Sep/2025
BioMarin Pharmaceutical USD 6.06B 29.6M Sep/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Canopy Growth CAD 736.01M 247.04M Sep/2025
Corcept Therapeutics USD 631.9M 3.89M Sep/2025
Eli Lilly USD 23.79B 5.52B Sep/2025
J&J USD 78.47B 0 Sep/2025
Knight Therapeutics CAD 773.91M 11.11M Sep/2024
Merck USD 51.85B 2.79B Sep/2025
Novartis USD 44.75B 2.7B Sep/2025
Novartis USD 44.33B 2.28B Sep/2025
Pacira USD 727.21M 30.55M Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
Supernus Pharmaceuticals USD 1.05B 14.23M Sep/2025
TG Therapeutics USD 607.22M 330.79M Sep/2025